Under these conditions, we found that CD33-CAR-T cells from AML patients presented a more exhausted phenotype, with increased PD1 and LAG3 expression, and a decreased proliferation potential that was statistically significant (Figures 3C, D, S4). Here, CD33 is linked to acute myeloid leukemia.